CLS: Rights issue outcome and coverage resumed - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

CLS: Rights issue outcome and coverage resumed - Redeye

{newsItem.title}

Redeye provides an update as we resume coverage after CLS’ rights issue. We give our thoughts on the capital raising, news during 2023, and our view of the Q1 report. We adjust our model accordingly to the rights issue outcome and make some changes in our estimates due to the report. We had estimated a rights issue; however, the dilution effect was significantly larger than we previously anticipated. Therefore, we lower our fair value range, including a new base case of SEK0.4 (1.3).

Länk till analysen i sin helhet: https://www.redeye.se/research/920491/cls-rights-issue-outcome-and-coverage-resumed?utm_source=finwire&utm_medium=RSS

Nyheter om Clinical Laserthermia

Läses av andra just nu

Om aktien Clinical Laserthermia

Senaste nytt